[The new features of meningococcal meningitis (author's transl)].
According to a previous pattern epidemics of meningococcal meningitis (MM) were localized in North tropical Africa, caused by A serotype, easily treated with sulfanilamides and prevented by a polyosidic vaccine, A type. Changes have occured : epidemics in Finland and Brazil, with an African A type germ, in place of the American, sulfa-resistant, C type; outburst of epidemics in South tropical Africa; presence of C type in Tchad, Niger and Nigeria. In the same time dramatic evolutions due to endotoxinic processes and drug-resistances are more frequently observed.
D000293:Adolescent; D000349:Africa; D001428:Bacterial Vaccines / Q000008:administration & dosage; D002648:Child; D002675:Child, Preschool; D006801:Humans; D008585:Meningitis, Meningococcal / Q000453:epidemiology / Q000517:prevention & control; D014611:Vaccination
D001428:Bacterial Vaccines
Le nouveau visage de la méningite à méningocoques.